Literature DB >> 30969100

Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Ana V Cheng1, William M Wuest1,2.   

Abstract

Innate and developed resistance mechanisms of bacteria to antibiotics are obstacles in the design of novel drugs. However, antibacterial prodrugs and conjugates have shown promise in circumventing resistance and tolerance mechanisms via directed delivery of antibiotics to the site of infection or to specific species or strains of bacteria. The selective targeting and increased permeability and accumulation of these prodrugs not only improves efficacy over unmodified drugs but also reduces off-target effects, toxicity, and development of resistance. Herein, we discuss some of these methods, including sideromycins, antibody-directed prodrugs, cell penetrating peptide conjugates, and codrugs.

Entities:  

Keywords:  antibody−antibiotic conjugate; cell penetrating peptide; dendrimer; oligopeptide; sideromycin; transferrin

Mesh:

Substances:

Year:  2019        PMID: 30969100      PMCID: PMC6570538          DOI: 10.1021/acsinfecdis.9b00019

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  106 in total

Review 1.  L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug.

Authors:  David S Goldstein
Journal:  Cardiovasc Drug Rev       Date:  2006 Fall-Winter

2.  Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Authors:  Leanna R Staben; Stefan G Koenig; Sophie M Lehar; Richard Vandlen; Donglu Zhang; Josefa Chuh; Shang-Fan Yu; Carl Ng; Jun Guo; Yanzhou Liu; Aimee Fourie-O'Donohue; MaryAnn Go; Xin Linghu; Nathaniel L Segraves; Tao Wang; Jinhua Chen; BinQing Wei; Gail D Lewis Phillips; Keyang Xu; Katherine R Kozak; Sanjeev Mariathasan; John A Flygare; Thomas H Pillow
Journal:  Nat Chem       Date:  2016-10-17       Impact factor: 24.427

Review 3.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

Review 4.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Squalenoyl nanomedicines as potential therapeutics.

Authors:  Patrick Couvreur; Barbara Stella; L Harivardhan Reddy; Hervé Hillaireau; Catherine Dubernet; Didier Desmaële; Sinda Lepêtre-Mouelhi; Flavio Rocco; Nathalie Dereuddre-Bosquet; Pascal Clayette; Véronique Rosilio; Véronique Marsaud; Jack-Michel Renoir; Luigi Cattel
Journal:  Nano Lett       Date:  2006-11       Impact factor: 11.189

6.  Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.

Authors:  Timothy A Wencewicz; Marvin J Miller
Journal:  J Med Chem       Date:  2013-05-08       Impact factor: 7.446

7.  Dual Targeting of Intracellular Pathogenic Bacteria with a Cleavable Conjugate of Kanamycin and an Antibacterial Cell-Penetrating Peptide.

Authors:  Anna Brezden; Mohamed F Mohamed; Manish Nepal; John S Harwood; Jerrin Kuriakose; Mohamed N Seleem; Jean Chmielewski
Journal:  J Am Chem Soc       Date:  2016-08-17       Impact factor: 15.419

8.  Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.

Authors:  Patrick J Burke; Joseph Z Hamilton; Thomas A Pires; Jocelyn R Setter; Joshua H Hunter; Julia H Cochran; Andrew B Waight; Kristine A Gordon; Brian E Toki; Kim K Emmerton; Weiping Zeng; Ivan J Stone; Peter D Senter; Robert P Lyon; Scott C Jeffrey
Journal:  Mol Cancer Ther       Date:  2016-03-04       Impact factor: 6.261

9.  Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.

Authors:  Zaineb A F Albayati; Manjula Sunkara; Suzannah M Schmidt-Malan; Melissa J Karau; Andrew J Morris; James M Steckelberg; Robin Patel; Philip J Breen; Mark S Smeltzer; K Grant Taylor; Kevyn E Merten; William M Pierce; Peter A Crooks
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

10.  Strategies for combating persister cell and biofilm infections.

Authors:  Thomas K Wood
Journal:  Microb Biotechnol       Date:  2017-07-11       Impact factor: 5.813

View more
  8 in total

Review 1.  Constructing and deconstructing the bacterial cell wall.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Protein Sci       Date:  2019-11-20       Impact factor: 6.725

2.  Pyochelin Biosynthetic Metabolites Bind Iron and Promote Growth in Pseudomonads Demonstrating Siderophore-like Activity.

Authors:  Anna R Kaplan; Djamaladdin G Musaev; William M Wuest
Journal:  ACS Infect Dis       Date:  2021-02-12       Impact factor: 5.084

3.  An allosteric inhibitor of bacterial Hsp70 chaperone potentiates antibiotics and mitigates resistance.

Authors:  Jordan Hosfelt; Aweon Richards; Meng Zheng; Carolina Adura; Brock Nelson; Amy Yang; Allison Fay; William Resager; Beatrix Ueberheide; J Fraser Glickman; Tania J Lupoli
Journal:  Cell Chem Biol       Date:  2021-11-23       Impact factor: 9.039

Review 4.  Crossroads of Antibiotic Resistance and Biosynthesis.

Authors:  Timothy A Wencewicz
Journal:  J Mol Biol       Date:  2019-07-06       Impact factor: 5.469

5.  Dual-targeted anti-CMV/anti-HIV-1 heterodimers.

Authors:  Anastasia L Khandazhinskaya; Vincenzo Mercurio; Anna A Maslova; Rogers Alberto Ñahui Palomino; Mikhail S Novikov; Elena S Matyugina; Maria P Paramonova; Marina K Kukhanova; Natalya E Fedorova; Kirill I Yurlov; Alla A Kushch; Olga Tarasova; Leonid Margolis; Sergey N Kochetkov; Christophe Vanpouille
Journal:  Biochimie       Date:  2021-06-29       Impact factor: 4.372

6.  Inhibitors of glucosamine-6-phosphate synthase as potential antimicrobials or antidiabetics - synthesis and properties.

Authors:  Joanna Stefaniak; Michał G Nowak; Marek Wojciechowski; Sławomir Milewski; Andrzej S Skwarecki
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 7.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649

Review 8.  New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.

Authors:  Thea Brennan-Krohn; Roman Manetsch; George A O'Doherty; James E Kirby
Journal:  Transl Res       Date:  2020-03-02       Impact factor: 7.012

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.